Eficácia e segurança da toxina botulínica tipo A no tratamento da neuralgia do trigêmeo refratária
Revista ft · 31.10.2026 · 30 (163) · 01-08
DOI: 10.69849/gy3p4815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 31.10.2026. Verfasst von Maria Eduarda Santana Bruneto und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Trigeminal neuralgia causes severe facial pain attacks that may persist despite pharmacological treatment. This article examines the efficacy and safety of botulinum toxin type A as an option for patients with insufficient response to conventional therapies. A narrative review of three scientific publications was conducted, focusing on pain reduction, duration of benefit, and adverse events. The findings indicate greater pain relief than placebo, with predominantly transient local reactions. However, treatment response may decline over time, and available studies are limited by sample size and follow-up duration. Botulinum toxin type A may be a promising complementary option in selected refractory cases, although evidence remains insufficient to define optimal dosing, reinjection intervals, and long-term safety.
Zitieren
APA
Bruneto, M. E. S., & Bruneto, J. V. S. (2026). Eficácia e segurança da toxina botulínica tipo A no tratamento da neuralgia do trigêmeo refratária. Revista ft, 30(163), 01-08. https://doi.org/10.69849/gy3p4815
Vancouver
Bruneto MES, Bruneto JVS. Eficácia e segurança da toxina botulínica tipo A no tratamento da neuralgia do trigêmeo refratária. Revista ft. 2026;30(163):01-08. doi:10.69849/gy3p4815
BibTeX
@article{Bruneto2026,
author = {Bruneto, Maria Eduarda Santana and Bruneto, João Victor Santana},
title = {Eficácia e segurança da toxina botulínica tipo A no tratamento da neuralgia do trigêmeo refratária},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {163},
pages = {01--08},
doi = {10.69849/gy3p4815}
}
EUVIMED